2024
Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
Al-Karaghouli M, Ventura-Cots M, Wong Y, Genesca J, Bosques F, Brown R, Mathurin P, Louvet A, Shawcross D, Vargas V, Verna E, Schnabl B, Caballeria J, Shah V, Kamath P, Lucey M, Garcia-Tsao G, Bataller R, Abraldes J. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design. Hepatology Communications 2024, 8: e0495. PMID: 39082963, DOI: 10.1097/hc9.0000000000000495.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisTrial designRandomized controlled trialsShort-term mortalityInclusion criteriaPredictive valuePrognostic valueControlled trialsShort-term benefitsEfficient trial designTrial outcomesAssociated with significant mortalityCourse of AHCohort of patientsTreatment decisionsSample sizeOrdinal outcomesMortalityOrdinal scaleMELD valuesLandmark analysisTransplant allocationTrialsOutcomesTransplantation
2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrialsSAT139 Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial
Bajaj J, Yeramian P, Gavis E, Fagan A, Fischer J, Garcia-Tsao G, Angeli P, Smith D, Adams J, Markham P. SAT139 Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial. Journal Of Hepatology 2020, 73: s718-s719. DOI: 10.1016/s0168-8278(20)31895-x.Peer-Reviewed Original Research
2019
LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension
Garcia-Tsao G, Bosch J, Kayali Z, Harrison S, Abdelmalek M, Lawitz E, Satapathy S, Ghabril M, Shiffman M, Younes Z, Thuluvath P, Berzigotti A, Albillos A, Robinson J, Chan J, Hagerty D, Sanyal A. LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension. Journal Of Hepatology 2019, 70: e127. DOI: 10.1016/s0618-8278(19)30225-7.Peer-Reviewed Original Research
2018
LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
Chalasani N, Garcia-Tsao G, Goodman Z, Lawitz E, Abdelmalek M, Rinella M, Ryan M, Noureddin M, Jue C, Pyko M, Allgood A, Shlevin H, Horton R, Zomer E, Traber P, Loomba R, Tetri B, Sanyal A, Harrison S. LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension. Journal Of Hepatology 2018, 68: s100-s101. DOI: 10.1016/s0168-8278(18)30420-3.Peer-Reviewed Original Research
2017
Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis
Albillos A, Zamora J, Martínez J, Arroyo D, Ahmad I, De‐la‐Peña J, Garcia‐Pagán J, Lo G, Sarin S, Sharma B, Abraldes JG, Bosch J, Garcia‐Tsao G, Cooperation O. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis. Hepatology 2017, 66: 1219-1231. PMID: 28543862, PMCID: PMC5605404, DOI: 10.1002/hep.29267.Peer-Reviewed Original ResearchConceptsChild B/CPrevious variceal bleedingCombination therapyVariceal bleedingCirrhosis severityChild APrognostic stageRecurrent variceal hemorrhageAdvanced liver failureEndoscopic variceal ligationOutcome of therapyVariceal hemorrhageLiver failureVariceal ligationLiver functionPatientsPatient careVaricealTherapyPatient dataMortalityTrialsCirrhosisBleedingProphylaxis
2016
Issues in Trial Design and Areas Needing Further Research
Abraldes J, Salerno F, Augustin S, Ripoll C, Reiberger T, Moreau R, Albillos A, Garcia-Tsao G. Issues in Trial Design and Areas Needing Further Research. 2016, 355-363. DOI: 10.1007/978-3-319-23018-4_35.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPrimary end pointVariceal bleedingEnd pointTrial designAppropriate primary end pointVariceal bleeding episodesComplications of cirrhosisNew therapeutic approachesBleeding episodesMultiple complicationsTherapeutic trialsCase mortalityTherapeutic approachesHigh riskLower riskPatientsClinical scenariosComplicationsBleedingPrevious trialsCirrhosisSecond complicationMortalityTrialsDeath
2006
Portal hypertension
Garcia-Tsao G. Portal hypertension. Current Opinion In Internal Medicine 2006, 5: 399-407. DOI: 10.1097/01.mog.0000218962.93806.9a.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPortal hypertensionVariceal bleedingTransjugular intrahepatic portosystemic shuntRecurrent variceal bleedingLarge-volume paracentesisSpontaneous bacterial peritonitisEndoscopic variceal ligationIntrahepatic portosystemic shuntHepatorenal syndromeRefractory ascitesBacterial peritonitisVariceal ligationSpecific complicationsPortosystemic shuntHypertensionΒ-blockersComplicationsTrialsBleedingVaricesAscitesDiagnosisRecent findingsRecent studiesCirrhosis
2005
Transjugular Intrahepatic Portosystemic Shunt (Tips) for the Management of Refractory Ascites in Cirrhosis
Garcia‐Tsao G. Transjugular Intrahepatic Portosystemic Shunt (Tips) for the Management of Refractory Ascites in Cirrhosis. 2005, 251-259. DOI: 10.1002/9780470987476.ch20.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2003
103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor
Groszmann R, Garcia-Tsao G, Makuch R, Bosch J, Escorsel A, Garcia-Pagan J, Grace N, Matloff D, Burroughs A, Patch D. 103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor. Hepatology 2003, 38: 206. DOI: 10.1016/s0270-9139(03)80146-5.Peer-Reviewed Original Research